↓ Skip to main content

Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Overview of attention for article published in BMC Infectious Diseases, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 5,409)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
47 news outlets
twitter
2 tweeters

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option
Published in
BMC Infectious Diseases, November 2016
DOI 10.1186/s12879-016-2013-1
Pubmed ID
Authors

Shuhui Cui, Ruoyan Gai Tobe, Xiuting Mo, Xiaoyan Liu, Lingzhong Xu, Shixue Li

Abstract

Rotavirus infection causes considerable disease burden of acute gastroenteritis (AGE) hospitalization and death among children less than 5 years in China. Although two rotavirus vaccines (Rotarix and RotaTeq) have been licensed in more than 100 countries in the world, the Lanzhou Lamb rotavirus vaccine (LLR) is the only vaccine licensed in China. This study aims to forecast the potential impacts of the two international vaccines compared to domestic LLR. An economic evaluation was performed using a Markov simulation model. We compared costs at the societal aspect and health impacts with and without a vaccination program by LLR, Rotarix or RotaTeq. Parameters including demographic, epidemiological data, costs and efficacy of vaccines were obtained from literature review. The model incorporated the impact of vaccination on reduction of incidence of rotavirus infection and severity of AGE indicated by hospitalization, inpatient visits and deaths. Outcomes are presented in terms of quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio (ICER) compared to status quo. In a hypothetical cohort of 100,000 infants, the two international vaccines showed very good cost-effectiveness, with ICER of Rotateq and Rotarix shifting from LLR of $1715.11/QALY and $2105.66/QALY, respectively. Rotateq and Rotarix had significantly decreased incidence compared to LLR, particularly among infants aged 6 months to 2 years. RotaTeq is expected to introduce in the national routine immunization program to reduce disease burden of rotavirus infection with universal coverage.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 24%
Student > Ph. D. Student 7 15%
Student > Bachelor 7 15%
Student > Master 7 15%
Student > Postgraduate 2 4%
Other 4 9%
Unknown 8 17%
Readers by discipline Count As %
Medicine and Dentistry 10 22%
Nursing and Health Professions 5 11%
Social Sciences 4 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Economics, Econometrics and Finance 3 7%
Other 7 15%
Unknown 14 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 380. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2018.
All research outputs
#32,335
of 14,547,674 outputs
Outputs from BMC Infectious Diseases
#7
of 5,409 outputs
Outputs of similar age
#1,808
of 374,981 outputs
Outputs of similar age from BMC Infectious Diseases
#2
of 578 outputs
Altmetric has tracked 14,547,674 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,409 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 578 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.